Synopsis
Synopsis
0
KDMF
0
VMF
DRUG PRODUCT COMPOSITIONS
Annual Reports
NA
Regulatory FDF Prices
NA
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Hydrochloride, Oxymetazoline
2. Oxymetazoline
1. 2315-02-8
2. Oxymetazoline Hcl
3. Ocuclear
4. Afrazine
5. Afrin Hydrochloride
6. Sch 9384
7. Rhofade
8. Oxymetazoline (hydrochloride)
9. Visine L.r.
10. Vicks Sinex
11. Nsc-757254
12. K89mj0s5vy
13. 6-tert-butyl-3-(4,5-dihydro-1h-imidazol-2-ylmethyl)-2,4-dimethylphenol;hydrochloride
14. Mls000038040
15. Chebi:7863
16. Agn-199201
17. Sch-9384
18. Smr000059324
19. 2-(4-t-butyl-2,6-dimethyl-3-hydroxybenzyl)-2-imidazolinium Chloride
20. 2,6-dimethyl-2-(4-tertiarybutyl-3-hydroxyphenyl)methylimidazoline Hydrochloride
21. 6-tert-butyl-3-(2-imidazolin-2-ylmethyl)-2,4-dimethylphenol Monohydrochloride
22. 6-tert-butyl-3-(4,5-dihydro-1h-imidazol-2-ylmethyl)-2,4-dimethylphenol Hydrochloride
23. Phenol, 3-((4,5-dihydro-1h-imidazol-2-yl)methyl)-6-(1,1-dimethylethyl)-2,4-dimethyl-, Monohydrochloride
24. 2-(3-hydroxy-2,6-dimethyl-4-tert-butylbenzyl)-2-imidazoline
25. Lliadine
26. Nasivin
27. Nasivine
28. Neonabel
29. Nostrilla
30. Nafrine Hydrochloride
31. 4-way Nasal Spray
32. Duration Nasal Spray
33. Oxymetazoline Chloride
34. Lliadin Mini Paediatric
35. Sr-01000002705
36. Neo-synephrine 12 Hour
37. Neo-synephrine 12 Hour Ntz
38. Sinex
39. Anefrin Nasal
40. Duration 12 Hour Nasal Spray
41. Benzedrex Nasal Spray 12 Hour
42. Dristan Long Lasting Nasal Mist
43. Sudafed Om
44. Ocuclear (tn)
45. Prestwick_373
46. Einecs 219-015-0
47. St. Joseph Nasal Spray For Children
48. Mfcd00058147
49. Rhfade (tn)
50. Upneeq
51. Opera_id_32
52. 2-(3-hydroxy-2,6-dimethyl-4-t-butylbenzyl)-2-imidazoline Hydrochloride
53. Unii-k89mj0s5vy
54. 3-[(4,5-dihydro-
55. Schembl41247
56. Mls002222207
57. Spectrum1500453
58. Oxymetazoline Hydrochloride,(s)
59. Chembl1200791
60. Hy-b0427a
61. Dtxsid80177729
62. Oximetazoline Hydrochloride
63. Hms1568n09
64. Hms1920d18
65. Pharmakon1600-01500453
66. Tox21_500903
67. Ccg-40216
68. Nsc757254
69. 6-t-butyl-3-(2-imidazolin-2-ylmethyl)-2,4-dimethylphenol Hydrochloride
70. Akos000280887
71. Oxymetazoline Hydrochloride (jan/usp)
72. Phenol, 6-t-butyl-3-(2-imidazolin-2-ylmethyl)-2,4-dimethyl-, Hydrochloride
73. Ks-5222
74. Lp00903
75. Nsc 757254
76. Oxymetazoline Hydrochloride [mi]
77. Ncgc00094218-01
78. Ncgc00094218-02
79. Ncgc00094218-03
80. Ncgc00094218-04
81. Ncgc00094218-05
82. Ncgc00261588-01
83. Oxymetazoline Hydrochloride [jan]
84. 2315-02-8 (hcl)
85. Oxymetazoline Hydrochloride [usan]
86. Oxymetazoline Hydrochloride [mart.]
87. Oxymetazoline Hydrochloride [vandf]
88. 4-(2-boc-amino-pyridin-4-yl)-benzoicacid
89. Oxymetazoline Hydrochloride [who-dd]
90. Oxymetazoline Hydrochloride, >=99%, Solid
91. Eu-0100903
92. Ft-0673462
93. O0520
94. Oxymetazoline Hydrochloride [usan:usp:jan]
95. Sw196632-3
96. D01022
97. D91882
98. O 2378
99. Oxymetazoline Hydrochloride, Analytical Standard
100. Oxymetazoline Hydrochloride [orange Book]
101. 315o028
102. A910982
103. Oxymetazoline Hydrochloride [ep Monograph]
104. Oxymetazoline Hydrochloride [usp Impurity]
105. Oxymetazoline Hydrochloride [usp Monograph]
106. Kovanaze Component Oxymetazoline Hydrochloride
107. Sr-01000002705-2
108. Sr-01000002705-4
109. Sr-01000002705-7
110. W-107424
111. Q27107602
112. Oxymetazoline Hydrochloride Component Of Kovanaze
113. Sinex Vapospray Moisturizing 12-hour Decongestant Ultrafine Mist
114. 2,6-dimethyl-4-tertiarybutyl-3-hydroxyphenyl)methylimidazoline Hydrochloride
115. 2-(4-tert-butyl-2,6-dimethyl-3-hydroxybenzyl)-2-imidazolinium Chloride
116. 6-tert-butyl-3-(2-imidazolin-2-ylmethyl)-2,4-dimethylphenol Hydrochloride
117. Oxymetazoline Hydrochloride, European Pharmacopoeia (ep) Reference Standard
118. 1h-imidazol-2-yl)methyl]-6-(1,1-dimethylethyl)-2,4-dimethylphenol Hydrochloride
119. 2-(3-hydroxy-2,6-dimethyl-4-tert-butylbenzyl)-2-imidazoline Hydrochloride
120. 2-(4-tert-butyl-3-hydroxy-2,6-dimethylbenzyl)-4,5-dihydro-1h-imidazol-1-ium Chloride
121. 6-(tert-butyl)-3-((4,5-dihydro-1h-imidazol-2-yl)methyl)-2,4-dimethylphenol Hydrochloride
122. 6-tert-butyl-3-((4,5-dihydro-1h-imidazol-2-yl)methyl)-2,4-dimethylphenol Hydrochloride
123. Oxymetazoline Hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material
124. Oxymetazoline Hydrochloride, United States Pharmacopeia (usp) Reference Standard
125. 3-[(4,5-dihydro-1h-imidazol-2-yl)methyl]-6-(1,1-dimethylethyl)-2,4-dimethyl-phenol Hydrochloride
Molecular Weight | 296.83 g/mol |
---|---|
Molecular Formula | C16H25ClN2O |
Hydrogen Bond Donor Count | 3 |
Hydrogen Bond Acceptor Count | 2 |
Rotatable Bond Count | 3 |
Exact Mass | 296.1655411 g/mol |
Monoisotopic Mass | 296.1655411 g/mol |
Topological Polar Surface Area | 44.6 Ų |
Heavy Atom Count | 20 |
Formal Charge | 0 |
Complexity | 345 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
Nasal Decongestants
Drugs designed to treat inflammation of the nasal passages, generally the result of an infection (more often than not the common cold) or an allergy related condition, e.g., hay fever. The inflammation involves swelling of the mucous membrane that lines the nasal passages and results in inordinate mucus production. The primary class of nasal decongestants are vasoconstrictor agents. (From PharmAssist, The Family Guide to Health and Medicine, 1993) (See all compounds classified as Nasal Decongestants.)
Sympathomimetics
Drugs that mimic the effects of stimulating postganglionic adrenergic sympathetic nerves. Included here are drugs that directly stimulate adrenergic receptors and drugs that act indirectly by provoking the release of adrenergic transmitters. (See all compounds classified as Sympathomimetics.)
Adrenergic alpha-Agonists
Drugs that selectively bind to and activate alpha adrenergic receptors. (See all compounds classified as Adrenergic alpha-Agonists.)
Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.
Date of Issue : 2025-07-24
Valid Till : 2028-07-21
Written Confirmation Number : WC-0150N
Address of the Firm :
Chynops Pharma is an ideal sourcing partner for high-quality APIs, advanced intermediates, speciality chemicals & excipients.
GDUFA
DMF Review : Reviewed
Rev. Date : 2019-02-15
Pay. Date : 2019-02-11
DMF Number : 8940
Submission : 1991-01-18
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 4290
Submission : 1981-10-08
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 4230
Submission : 1981-06-15
Status : Inactive
Type : II
Certificate Number : R1-CEP 2008-064 - Rev 02
Issue Date : 2021-01-15
Type : Chemical
Substance Number : 943
Status : Valid
Registration Number : 220MF10107
Registrant's Address : Karlstrasse 15, 32423, Minden, Federal Republic of Germany
Initial Date of Registration : 2008-04-11
Latest Date of Registration :
NDC Package Code : 65724-4503
Start Marketing Date : 2010-03-02
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Date of Issue : 2025-07-11
Valid Till : 2028-07-02
Written Confirmation Number : WC-0097
Address of the Firm :
GDUFA
DMF Review : Complete
Rev. Date : 2015-09-18
Pay. Date : 2013-01-04
DMF Number : 22401
Submission : 2008-12-10
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 4290
Submission : 1981-10-08
Status : Inactive
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2019-02-15
Pay. Date : 2019-02-11
DMF Number : 8940
Submission : 1991-01-18
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 4230
Submission : 1981-06-15
Status : Inactive
Type : II
Certificate Number : R1-CEP 2008-324 - Rev 03
Status : Valid
Issue Date : 2018-05-18
Type : Chemical
Substance Number : 943
Certificate Number : R1-CEP 2008-064 - Rev 02
Status : Valid
Issue Date : 2021-01-15
Type : Chemical
Substance Number : 943
Registration Number : 220MF10107
Registrant's Address : Karlstrasse 15, 32423, Minden, Federal Republic of Germany
Initial Date of Registration : 2008-04-11
Latest Date of Registration : 2024-02-21
Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.
Oxymetazoline Hydrochloride Ph. Eur
Date of Issue : 2025-07-24
Valid Till : 2028-07-21
Written Confirmation Number : WC-0150N
Address of the Firm : API Unit-l, R.S. No. 50/1, Mukteswarapuram Village,\r\nJaggaiahpet Mandal, NTR D...
Oxymetazoline Hydrochloride Ph.Eur.
Date of Issue : 2025-07-11
Valid Till : 2028-07-02
Written Confirmation Number : WC-0097
Address of the Firm : Block No. 251/B, 252/B, 253, 254, 255, 256, 258/B, 276, 277, 278/P, 279, 280, 28...
Oxymetazoline Hydrochloride BP/USP/Ph. Eur
Date of Issue : 2025-07-11
Valid Till : 2028-07-02
Written Confirmation Number : WC-0097
Address of the Firm : Block No. 251/B, 252/B, 253, 254, 255, 256, 258/B, 276, 277, 278/P, 279, 280, 28...
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
Oxymetazoline HCl is a Other Small Molecule drug candidate, which is currently being evaluated in Phase IV clinical studies for the treatment of unspecified medical condition.
Lead Product(s): Oxymetazoline Hydrochloride,Inapplicable
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Miscellaneous
Sponsor: Child and Adolescent Health Service - Perth | Sao Paulo Clinical Hospital - SP | Rigshospitalet
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 03, 2025
Lead Product(s) : Oxymetazoline Hydrochloride,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Child and Adolescent Health Service - Perth | Sao Paulo Clinical Hospital - SP | Rigshospitalet
Deal Size : Inapplicable
Deal Type : Inapplicable
Nasal Decongestant Safety In Children with URTIs During Anesthesia
Details : Oxymetazoline HCl is a Other Small Molecule drug candidate, which is currently being evaluated in Phase IV clinical studies for the treatment of unspecified medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 03, 2025
Details:
Oxymetazoline HCl is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Blepharophimosis.
Lead Product(s): Oxymetazoline Hydrochloride,Inapplicable
Therapeutic Area: Ophthalmology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 23, 2024
Lead Product(s) : Oxymetazoline Hydrochloride,Inapplicable
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Oxymetazoline HCl is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Blepharophimosis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 23, 2024
Details:
LEV102 (oxymetazoline) is an adrenergic α1- and α2-agonist and a direct-acting sympathomimetic, causing vasoconstriction of dilated arterioles and reduces blood flow. It is currently being investigated in phase I/II clinical trial for acquired blepharoptosis.
Lead Product(s): Oxymetazoline Hydrochloride,Inapplicable
Therapeutic Area: Ophthalmology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 27, 2023
Lead Product(s) : Oxymetazoline Hydrochloride,Inapplicable
Therapeutic Area : Ophthalmology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Levation Pharma Initiates Phase I/II Clinical Trial of LEV102 for Acquired Blepharoptosis
Details : LEV102 (oxymetazoline) is an adrenergic α1- and α2-agonist and a direct-acting sympathomimetic, causing vasoconstriction of dilated arterioles and reduces blood flow. It is currently being investigated in phase I/II clinical trial for acquired blepharo...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 27, 2023
Details:
Rhofade (oxymetazoline hydrochloride) cream is an FDA-approved prescription topical treatment that may reduce persistent facial redness by at least two grades, according to both doctor and patient scales that evaluated rosacea redness in two 29-day trials in adults.
Lead Product(s): Oxymetazoline Hydrochloride,Inapplicable
Therapeutic Area: Dermatology Brand Name: Rhofade
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Sato Yakuhin Kogyo Co., Ltd
Deal Size: $7.5 million Upfront Cash: $5.0 million
Deal Type: Licensing Agreement December 21, 2022
Lead Product(s) : Oxymetazoline Hydrochloride,Inapplicable
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Sato Yakuhin Kogyo Co., Ltd
Deal Size : $7.5 million
Deal Type : Licensing Agreement
Details : Rhofade (oxymetazoline hydrochloride) cream is an FDA-approved prescription topical treatment that may reduce persistent facial redness by at least two grades, according to both doctor and patient scales that evaluated rosacea redness in two 29-day trial...
Product Name : Rhofade
Product Type : Miscellaneous
Upfront Cash : $5.0 million
December 21, 2022
Details:
Afrin® (oxymetazoline hydrochloride) provides targeted fast relief, for children who suffer from nasal congestion due to colds or allergies. Afrin® Extra Moisturizing Stuffy Nose Pump Mist, for ages two to six years old unblocks a stuffy nose fast.
Lead Product(s): Oxymetazoline Hydrochloride,Inapplicable
Therapeutic Area: Infections and Infectious Diseases Brand Name: Afrin
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 17, 2022
Lead Product(s) : Oxymetazoline Hydrochloride,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Afrin® WOWs Parents with Launch of Children’s Acute Medicated Nasal Sprays – Because One Sick...
Details : Afrin® (oxymetazoline hydrochloride) provides targeted fast relief, for children who suffer from nasal congestion due to colds or allergies. Afrin® Extra Moisturizing Stuffy Nose Pump Mist, for ages two to six years old unblocks a stuffy nose fast.
Product Name : Afrin
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 17, 2022
Details:
Oxymetazoline HCl is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Common Cold.
Lead Product(s): Oxymetazoline Hydrochloride,Inapplicable
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 27, 2022
Lead Product(s) : Oxymetazoline Hydrochloride,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Otrivine: Quality of Life (QoL) Impact in a Real-World Setting
Details : Oxymetazoline HCl is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Common Cold.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 27, 2022
Details:
As another company invested in optimal patient health, RVL Pharmaceuticals offers appropriate patients a nonsurgical solution for acquired ptosis and provides results in as fast as 5 minutes with UPNEEQ (oxymetazoline hydrochloride ophthalmic solution).
Lead Product(s): Oxymetazoline Hydrochloride,Inapplicable
Therapeutic Area: Ophthalmology Brand Name: Upneeq
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: RVL Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership August 30, 2022
Lead Product(s) : Oxymetazoline Hydrochloride,Inapplicable
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : RVL Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Partnership
Revision Skincare® Announces Strategic Partnership with RVL Pharmaceuticals, Inc.
Details : As another company invested in optimal patient health, RVL Pharmaceuticals offers appropriate patients a nonsurgical solution for acquired ptosis and provides results in as fast as 5 minutes with UPNEEQ (oxymetazoline hydrochloride ophthalmic solution).
Product Name : Upneeq
Product Type : Miscellaneous
Upfront Cash : Undisclosed
August 30, 2022
Details:
The financing reflects in the brand and enhances the financial position as build momentum with the expanded launch of UPNEEQ (oxymetazoline hydrochloride). Provider and patient feedback continue to be positive as UPNEEQ awareness grows.
Lead Product(s): Oxymetazoline Hydrochloride,Inapplicable
Therapeutic Area: Ophthalmology Brand Name: Upneeq
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Athyrium Capital
Deal Size: $24.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement August 04, 2022
Lead Product(s) : Oxymetazoline Hydrochloride,Inapplicable
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Athyrium Capital
Deal Size : $24.0 million
Deal Type : Private Placement
RVL Pharmaceuticals Plc Announces Insider and Athyrium-Led Financing
Details : The financing reflects in the brand and enhances the financial position as build momentum with the expanded launch of UPNEEQ (oxymetazoline hydrochloride). Provider and patient feedback continue to be positive as UPNEEQ awareness grows.
Product Name : Upneeq
Product Type : Miscellaneous
Upfront Cash : Undisclosed
August 04, 2022
Details:
Acquisition forward integrates Novan with complementary commercial infrastructure to drive commercial launch of SB206, subject to regulatory approval, for the treatment of molluscum contagiosum.
Lead Product(s): Oxymetazoline Hydrochloride,Inapplicable
Therapeutic Area: Dermatology Brand Name: Rhofade
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Novan
Deal Size: $51.0 million Upfront Cash: $27.5 million
Deal Type: Acquisition March 11, 2022
Lead Product(s) : Oxymetazoline Hydrochloride,Inapplicable
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Novan
Deal Size : $51.0 million
Deal Type : Acquisition
Novan Acquires EPI Health, a Specialty Dermatology Company
Details : Acquisition forward integrates Novan with complementary commercial infrastructure to drive commercial launch of SB206, subject to regulatory approval, for the treatment of molluscum contagiosum.
Product Name : Rhofade
Product Type : Miscellaneous
Upfront Cash : $27.5 million
March 11, 2022
Details:
Oxymetazoline HCl is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): Oxymetazoline Hydrochloride,Inapplicable
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 08, 2021
Lead Product(s) : Oxymetazoline Hydrochloride,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study Comparing Oxymetazoline 1% Cream to RHOFADE
Details : Oxymetazoline HCl is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 08, 2021
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
Regulatory Info : Cancelled
Registration Country : Spain
Brand Name : Nebulicine
Dosage Form : Nasal Spray Solution
Dosage Strength : 0.5MG
Packaging :
Approval Date : 1970-01-01
Application Number : 48818
Regulatory Info : Cancelled
Registration Country : Spain
Regulatory Info : Originator
Registration Country : South Africa
Brand Name : Oxylin Liquifilm Sterile Ophthalmic Solution
Dosage Form : OPD
Dosage Strength : 5mg/ml
Packaging : 15X1mg/ml
Approval Date :
Application Number :
Regulatory Info : Originator
Registration Country : South Africa
Regulatory Info :
Registration Country : Australia
Brand Name : Logicin Rapid Relief
Dosage Form : nasal spray
Dosage Strength : 0.05%
Packaging : 1
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Octavius Pharma has been empowering lives since 1980 by providing quality products like DC granules, APIs and FDFs.
Regulatory Info :
Registration Country : India
Brand Name : Oxymetazoline Hydrochloride
Dosage Form : Nasal Solution
Dosage Strength : 0.05%
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Regulatory Info : DISCN
Registration Country : USA
Brand Name : OCUCLEAR
Dosage Form : SOLUTION/DROPS;OPHTHALMIC
Dosage Strength : 0.025%
Packaging :
Approval Date : 1986-05-30
Application Number : 18471
Regulatory Info : DISCN
Registration Country : USA
Regulatory Info : RX
Registration Country : USA
Brand Name : RHOFADE
Dosage Form : CREAM;TOPICAL
Dosage Strength : 1%
Packaging :
Approval Date : 2017-01-18
Application Number : 208552
Regulatory Info : RX
Registration Country : USA
Regulatory Info : RX
Registration Country : USA
Brand Name : UPNEEQ
Dosage Form : SOLUTION/DROPS;OPHTHALMIC
Dosage Strength : 0.1%
Packaging :
Approval Date : 2020-07-08
Application Number : 212520
Regulatory Info : RX
Registration Country : USA
Regulatory Info : RX
Registration Country : USA
OXYMETAZOLINE HYDROCHLORIDE; TETRACAINE HYDROCHLORIDE
Brand Name : KOVANAZE
Dosage Form : SPRAY, METERED;NASAL
Dosage Strength : 0.1MG/SPRAY;6MG/SPRAY
Packaging :
Approval Date : 2016-06-29
Application Number : 208032
Regulatory Info : RX
Registration Country : USA
Regulatory Info : DISCN
Registration Country : USA
Brand Name : OXYMETAZOLINE HYDROCHLORIDE
Dosage Form : CREAM;TOPICAL
Dosage Strength : 1%
Packaging :
Approval Date : 2021-10-04
Application Number : 213584
Regulatory Info : DISCN
Registration Country : USA
Regulatory Info :
Registration Country : USA
Brand Name : OXYMETAZOLINE
Dosage Form : CREAM;TOPICAL
Dosage Strength : 1%
Packaging :
Approval Date :
Application Number : 211812
Regulatory Info :
Registration Country : USA
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
CAS Number : n/a
Quantity Per Vial : 15 mg
Sale Unit : 1
Order Code : Y0001044
Batch No : 2
Price (€) : 79
Storage : +5°C ± 3°C
CAS Number : 2315-02-8
Quantity Per Vial : 80 mg
Sale Unit : 1
Order Code : O0290000
Batch No : 2
Price (€) : 79
Storage : +5°C ± 3°C
Sigma-Aldrich empowers scientific discovery with top-quality solutions to accelerate research, innovation, and better health worldwide.
CAS Number : 2315-02-8
Quantity Per Vial :
Sale Unit :
Price : $566.00
Details :
Monograph : PHR1572-10G
Storage : +2°C to +30°C
Code/Batch No :
Sigma-Aldrich empowers scientific discovery with top-quality solutions to accelerate research, innovation, and better health worldwide.
CAS Number : 2315-02-8
Quantity Per Vial :
Sale Unit :
Price : $134.00
Details :
Monograph : PHR1572-500MG
Storage : +2°C to +30°C
Code/Batch No :
Sigma-Aldrich empowers scientific discovery with top-quality solutions to accelerate research, innovation, and better health worldwide.
Oxymetazoline Related Compound A
CAS Number : 1391053-50-1
Quantity Per Vial :
Sale Unit :
Price : $947.00
Details :
Monograph : PHR2215-100MG
Storage : +2°C to +8°C
Code/Batch No :
Sigma-Aldrich empowers scientific discovery with top-quality solutions to accelerate research, innovation, and better health worldwide.
2-(4-tert-Butyl-3-hydroxy-2,6-dimethylphenyl)...
CAS Number : 55699-10-0
Quantity Per Vial :
Sale Unit :
Price : $518.00
Details :
Monograph : PHR9161-50MG
Storage : -10°C to -25°C
Code/Batch No :
Oxymetazoline Related Compound A
CAS Number : 1391194-44-7
Quantity Per Vial :
Sale Unit :
Price :
Details : In stock
Monograph :
Storage :
Code/Batch No : O0007.06
CAS Number :
Quantity Per Vial :
Sale Unit :
Price : $947.00
Details :
Monograph : PHR2215-100MG
Storage : +2?C to +8?C
Code/Batch No :
CAS Number :
Quantity Per Vial :
Sale Unit :
Price : $134.00
Details :
Monograph : PHR1572-500MG
Storage : +2?C to +30?C
Code/Batch No :
CAS Number :
Quantity Per Vial :
Sale Unit :
Price : $566.00
Details :
Monograph : PHR1572-10G
Storage : +2?C to +30?C
Code/Batch No :
ABOUT THIS PAGE
30
PharmaCompass offers a list of Oxymetazoline Hydrochloride API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Oxymetazoline Hydrochloride manufacturer or Oxymetazoline Hydrochloride supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Oxymetazoline Hydrochloride manufacturer or Oxymetazoline Hydrochloride supplier.
PharmaCompass also assists you with knowing the Oxymetazoline Hydrochloride API Price utilized in the formulation of products. Oxymetazoline Hydrochloride API Price is not always fixed or binding as the Oxymetazoline Hydrochloride Price is obtained through a variety of data sources. The Oxymetazoline Hydrochloride Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Anefrin nasal manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Anefrin nasal, including repackagers and relabelers. The FDA regulates Anefrin nasal manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Anefrin nasal API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Anefrin nasal manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Anefrin nasal supplier is an individual or a company that provides Anefrin nasal active pharmaceutical ingredient (API) or Anefrin nasal finished formulations upon request. The Anefrin nasal suppliers may include Anefrin nasal API manufacturers, exporters, distributors and traders.
click here to find a list of Anefrin nasal suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Anefrin nasal DMF (Drug Master File) is a document detailing the whole manufacturing process of Anefrin nasal active pharmaceutical ingredient (API) in detail. Different forms of Anefrin nasal DMFs exist exist since differing nations have different regulations, such as Anefrin nasal USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Anefrin nasal DMF submitted to regulatory agencies in the US is known as a USDMF. Anefrin nasal USDMF includes data on Anefrin nasal's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Anefrin nasal USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Anefrin nasal suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Anefrin nasal Drug Master File in Japan (Anefrin nasal JDMF) empowers Anefrin nasal API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Anefrin nasal JDMF during the approval evaluation for pharmaceutical products. At the time of Anefrin nasal JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Anefrin nasal suppliers with JDMF on PharmaCompass.
A Anefrin nasal CEP of the European Pharmacopoeia monograph is often referred to as a Anefrin nasal Certificate of Suitability (COS). The purpose of a Anefrin nasal CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Anefrin nasal EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Anefrin nasal to their clients by showing that a Anefrin nasal CEP has been issued for it. The manufacturer submits a Anefrin nasal CEP (COS) as part of the market authorization procedure, and it takes on the role of a Anefrin nasal CEP holder for the record. Additionally, the data presented in the Anefrin nasal CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Anefrin nasal DMF.
A Anefrin nasal CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Anefrin nasal CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Anefrin nasal suppliers with CEP (COS) on PharmaCompass.
A Anefrin nasal written confirmation (Anefrin nasal WC) is an official document issued by a regulatory agency to a Anefrin nasal manufacturer, verifying that the manufacturing facility of a Anefrin nasal active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Anefrin nasal APIs or Anefrin nasal finished pharmaceutical products to another nation, regulatory agencies frequently require a Anefrin nasal WC (written confirmation) as part of the regulatory process.
click here to find a list of Anefrin nasal suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Anefrin nasal as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Anefrin nasal API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Anefrin nasal as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Anefrin nasal and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Anefrin nasal NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Anefrin nasal suppliers with NDC on PharmaCompass.
Anefrin nasal Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Anefrin nasal GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Anefrin nasal GMP manufacturer or Anefrin nasal GMP API supplier for your needs.
A Anefrin nasal CoA (Certificate of Analysis) is a formal document that attests to Anefrin nasal's compliance with Anefrin nasal specifications and serves as a tool for batch-level quality control.
Anefrin nasal CoA mostly includes findings from lab analyses of a specific batch. For each Anefrin nasal CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Anefrin nasal may be tested according to a variety of international standards, such as European Pharmacopoeia (Anefrin nasal EP), Anefrin nasal JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Anefrin nasal USP).